Target Price | $117.30 |
Price | $100.15 |
Potential | 17.12% |
Number of Estimates | 32 |
32 Analysts have issued a price target Lam Research 2026 . The average Lam Research target price is $117.30. This is 17.12% higher than the current stock price. The highest price target is $141.75 41.54% , the lowest is $80.80 19.32% . | |
A rating was issued by 39 analysts: 30 Analysts recommend Lam Research to buy, 9 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Lam Research stock has an average upside potential 2026 of 17.12% . Most analysts recommend the Lam Research stock at Purchase. |
34 Analysts have issued a sales forecast Lam Research 2026 . The average Lam Research sales estimate is $20.3b . This is 10.18% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $21.6b 17.09% , the lowest is $18.1b 2.09% .
This results in the following potential growth metrics:
2025 | $18.4b | 23.68% |
---|---|---|
2026 | $20.3b | 10.18% |
2027 | $22.3b | 9.80% |
2028 | $24.0b | 7.68% |
2029 | $27.1b | 13.03% |
2030 | $27.2b | 0.28% |
21 Analysts have issued an Lam Research EBITDA forecast 2026. The average Lam Research EBITDA estimate is $6.8b . This is 8.12% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $7.5b 19.59% , the lowest is $5.2b 16.99% .
This results in the following potential growth metrics and future EBITDA Margins:
2025 | $6.3b | 34.19% |
---|---|---|
2026 | $6.8b | 8.12% |
2027 | $7.7b | 13.18% |
2028 | $8.5b | 10.61% |
2029 | $9.8b | 15.70% |
2030 | $9.5b | 3.73% |
2025 | 34.10% | 8.50% |
---|---|---|
2026 | 33.47% | 1.86% |
2027 | 34.50% | 3.08% |
2028 | 35.43% | 2.70% |
2029 | 36.27% | 2.37% |
2030 | 34.82% | 4.00% |
34 Lam Research Analysts have issued a net profit forecast 2026. The average Lam Research net profit estimate is $5.8b . This is 7.90% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $6.4b 20.08% , the lowest is $5.0b 5.79% .
This results in the following potential growth metrics and future Net Margins:
2025 | $5.4b | 39.98% |
---|---|---|
2026 | $5.8b | 7.90% |
2027 | $6.6b | 13.98% |
2028 | $7.4b | 12.71% |
2029 | $9.7b | 31.01% |
2025 | 29.06% | 13.18% |
---|---|---|
2026 | 28.46% | 2.08% |
2027 | 29.55% | 3.83% |
2028 | 30.93% | 4.67% |
2029 | 35.85% | 15.91% |
34 Analysts have issued a Lam Research forecast for earnings per share. The average Lam Research EPS is $4.56 . This is 8.83% higher than earnings per share in the financial year 2025. The highest EPS forecast is $5.07 21.00% , the lowest is $3.98 5.01% .
This results in the following potential growth metrics and future valuations:
2025 | $4.15 | 43.10% |
---|---|---|
2026 | $4.56 | 9.88% |
2027 | $5.19 | 13.82% |
2028 | $5.85 | 12.72% |
2029 | $7.67 | 31.11% |
Current | 23.90 | 18.20% |
---|---|---|
2026 | 21.98 | 8.04% |
2027 | 19.28 | 12.28% |
2028 | 17.11 | 11.26% |
2029 | 13.06 | 23.67% |
Based on analysts' sales estimates for 2026, the Lam Research stock is valued at an EV/Sales of 6.15 and an P/S ratio of 6.24 .
This results in the following potential growth metrics and future valuations:
Current | 6.77 | 7.64% |
---|---|---|
2026 | 6.15 | 9.22% |
2027 | 5.60 | 8.93% |
2028 | 5.20 | 7.13% |
2029 | 4.60 | 11.53% |
2030 | 4.59 | 0.28% |
Current | 6.88 | 6.88% |
---|---|---|
2026 | 6.24 | 9.24% |
2027 | 5.68 | 8.93% |
2028 | 5.28 | 7.13% |
2029 | 4.67 | 11.53% |
2030 | 4.66 | 0.28% |
Analyst | Rating | Action | Date |
---|---|---|---|
Cantor Fitzgerald |
Overweight
➜
Overweight
|
Unchanged | Aug 21 2025 |
Argus Research |
Buy
➜
Buy
|
Unchanged | Aug 01 2025 |
Mizuho |
Outperform
➜
Outperform
|
Unchanged | Aug 01 2025 |
Citigroup |
Buy
➜
Buy
|
Unchanged | Aug 01 2025 |
Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Jul 31 2025 |
Oppenheimer |
Outperform
➜
Outperform
|
Unchanged | Jul 31 2025 |
Needham |
Buy
➜
Buy
|
Unchanged | Jul 31 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Cantor Fitzgerald:
Overweight
➜
Overweight
|
Aug 21 2025 |
Unchanged
Argus Research:
Buy
➜
Buy
|
Aug 01 2025 |
Unchanged
Mizuho:
Outperform
➜
Outperform
|
Aug 01 2025 |
Unchanged
Citigroup:
Buy
➜
Buy
|
Aug 01 2025 |
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Jul 31 2025 |
Unchanged
Oppenheimer:
Outperform
➜
Outperform
|
Jul 31 2025 |
Unchanged
Needham:
Buy
➜
Buy
|
Jul 31 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.